arcoris bio Launches ImmunoMUSE, Enabling Flexible, High-Sensitivity Multiplex Immunofluorescence With User-Defined Antibodies

arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced the launch of its immunoMUSE kits, based on its breakthrough MUSE biomarker detection platform. With immunoMUSE, researchers can create their own multiplex immunofluorescence panels using their preferred antibodies, combining flexibility with high sensitivity and ease of use.

arcoris bio’s MUSE technology enables simultaneous detection of multiple biomarkers with exceptional sensitivity and simplified workflows. By supporting the detection of low-abundance targets within a single sample and enabling higher throughput, MUSE is well positioned to advance applications in digital pathology and translational research.

“With immunoMUSE, we put control over multiplex panel design directly into the hands of researchers,” said Simon Restrepo, CSO at arcoris bio. “Users can now leverage their own validated antibodies while benefiting from the sensitivity, scalability, and simplicity of the MUSE platform.”

arcoris bio will present immunoMUSE at the European Association for Cancer Research (EACR) Annual Congress 2026, taking place June 8-11 in Budapest, Hungary. Attendees are invited to visit the arcoris bio team at booth 63 to learn more and discuss with the experts how MUSE is shaping the future of biomarker detection.

About immunoMUSE
Compared to conventional staining approaches, immunoMUSE improves signal-to-noise ratios, enabling more reliable detection of low-abundance biomarkers and increasing overall assay sensitivity.

It is well-suited for a broad range of research applications, including:

• Oncology: profiling tumor microenvironments and identifying rare or low-abundance biomarkers
• Neurobiology: studying complex neuronal networks and subtle protein expression patterns
• Immunology: characterizing immune cell populations and their interactions
• Spatial biology: enabling multiplexed biomarker analysis while preserving spatial context within tissues

The portfolio includes:

• Activate & Amplify kits: providing all reagents required to prepare user antibodies for use with the MUSE system and perform staining
• Amplify kits: additional amplification reagents for expanded workflows

About arcoris bio
arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology. The company is headquartered in Schlieren, Switzerland.

For more information, visit: www.arcorisbio.com